Cardiotoxicity in Hematological Diseases: Are the Tyrosine Kinase Inhibitors Imatinib and Nilotinib Safe?

Overview of attention for article published in Cardiovascular Toxicology, April 2018

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#20 of 280)
Good Attention Score compared to outputs of the same age (73rd percentile)
High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

news: 1 news outlet

Citations

dimensions_citation: 7 Dimensions

Readers on

mendeley: 29 Mendeley

Summary News Dimensions citations

So far, Altmetric has seen 1 news story.

1-year Imatinib or Nilotinib Therapy Not Associated with Cardiotoxity in CML

Oncology Nurse Advisor , 09 Apr 2018

April 09, 2018 The negative cardiac effects of imatinib and nilotinib have not been fully researched.

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.